Zimmer Biomet Q4 sales up 10.9%, diluted EPS down 41.7% to $0.70; sets 2026 outlook
Zimmer Biomet reported fourth-quarter 2025 net sales of $2.244 billion, up 10.9%, while GAAP diluted EPS fell 41.7% to $0.70; adjusted diluted EPS rose 4.8% to $2.42. For full-year 2025, net sales were $8.232 billion (up 7.2%) and GAAP diluted EPS was $3.55 (down 19.9%). The company guided 2026 reported revenue growth of 2.5% to 4.5% and adjusted diluted EPS of $8.30 to $8.45, and its board approved a repurchase authorization of up to $1.5 billion.
Key points
- Q4 2025 net sales $2.244 billion, up 10.9% reported and 5.4% organic constant currency
- Q4 GAAP diluted EPS $0.70 versus $1.20 a year earlier; Q4 operating profit $154.5 million versus $389.0 million
- 2026 guidance: reported revenue change 2.5% to 4.5%; adjusted diluted EPS $8.30 to $8.45 versus $8.20 in 2025
- Board approved buyback of up to $1.5 billion starting February 9, 2026, with no expiration; $250 million repurchased in Q4 2025
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.